drugset / Trial / NCT05159453
Dose Response Study of Transdermal Human Insulin in Patients
Phase 2/3
Not yet recruiting
30 enrolled
Transdermal Delivery Solutions Corp
Langford Research Institute, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
A 21-Day open label study of transdermally delivered human insulin in Type 2 Diabetics as measured by response of down modulation of glucose after dosing of Insulin as compared to historic patient response to injected insulins.
Timeline
- Start
- 2027-09-02
- Primary completion
- 2027-10-15
- Completion
- 2027-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin | Protein / enzyme biologic | 20 iu | Other |